Virtual CME Program

1.00 CME/CE Credit

MASLD and MASH Management: A Primary Care Priority

Why are MASLD and MASH such important considerations in the primary setting, and how should PCPs approach management of these conditions? In this interactive case-based webinar, expert faculty will discuss recommended approaches to diagnosis, risk stratification, treatment, and referral, and review the evidence supporting the recommendations.

Begin

CME/CE Information

1.00 AMA PRA Category 1 Credits™, including 1.00 AAFP Prescribed Credits, 1.00 ABIM MOC or 1.00 AANP, including 0.50 AANP Pharm

Release Date: 9/24/2025

Expiration Date: 9/24/2026

Topics

Hepatology

Learning Objectives

Identify individuals who should be screened for MASLD and MASH in the primary care setting
Apply NITs and biomarkers for optimal assessment, risk stratification, and monitoring of MASLD and MASH
Implement guideline-recommended strategies for managing MASLD and MASH, including treatment of comorbid metabolic conditions and collaboration with specialists when needed
Discuss evidence supporting the use of recommended pharmacotherapies with proven efficacy in MASH

Faculty

Eugene E. Wright Jr., MD

Medical Director for Performance Improvement, South Piedmont Area Health Education Center

Learn More

Manal Abdelmalek, MD

Professor of Medicine, Mayo Clinic, Rochester, MN

Director, MASLD Clinical Research Program, Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN

Learn More

Disclosures

The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All have been mitigated by Pri-Med Institute:

Eugene E. Wright, Jr., MD: Speaker for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Lilly, Sanofi, Embecta; Advisor for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Lilly, Sanofi, Embecta; Consultant for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Lilly, Sanofi, Embecta

Manal F. Abdelmalek, MD, MPH: Researcher for Akero, 89Bio, Gilead, Hanmi, Inventiva, Novo Nordisk, Madrigal; Advisor for 89Bio, Novo Nordisk, Madrigal, Hanmi, Inventia, Medscape; Speaker for Clinical Care Options, Fishawack LLC, Medscape

Ty Gluckman, MD, MHA, FACC, FAHA, FASPC (Moderator): Consultant for OptumRx and Premier

All others in control of content for this activity have disclosed no relevant financial relationships.

CME/CE Information

AMA PRA Category 1 Credits™

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Institute for Medical and Nursing Education (IMNE). Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits

Accreditation Statement

The AAFP has reviewed MASLD and MASH Management: A Primary Care Priority and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 09/24/2025 to 09/24/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Institute for Medical and Nursing Education (IMNE) Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308

Designation Statement

This activity is approved for 1.00 contact hour of continuing education, which includes 0.50 hours of pharmacology.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 4 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Supported by

Novo Nordisk Inc.

Education Partners

Institute for Medical and Nursing Education, Inc.

Pri-Med Institute

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.